Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Sponsor: Fred Hutchinson Cancer Center
Summary
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
Official title: Rifaximin Versus No Intervention in Patients With IgA Monoclonal Gammopathy of Undetermined Significance
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-01-22
Completion Date
2028-05-01
Last Updated
2026-01-27
Healthy Volunteers
No
Interventions
Rifaximin
Given PO
Biospecimen Collection
Undergo blood sample collection
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States